| AUY922 in Patient With Stage IV NSCLC (NCT01922583) | National Taiwan University Hospital | 2014-01-01 |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) (NCT01999985) | H. Lee Moffitt Cancer Center and Research Institute | 2013-12-31 |
| Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients (NCT02016872) | Memorial Sloan Kettering Cancer Center | 2013-12-16 |
| An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (NCT01964157) | Yonsei University | 2013-09-01 |
| Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) (NCT01905657) | Merck Sharp & Dohme LLC | 2013-08-09 |
| Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients (NCT01980472) | Grupo de Investigación y Divulgación Oncológica | 2013-08-01 |
| Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab (NCT02316327) | Fundacion Clinic per a la Recerca Biomédica | 2013-07-01 |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel (NCT01702844) | UNC Lineberger Comprehensive Cancer Center | 2013-06-25 |
| Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) (NCT01741155) | Spectrum Pharmaceuticals, Inc | 2013-05-01 |
| Powered Echelon Device in VATS Surgery (NCT01843192) | Ethicon Endo-Surgery | 2013-05-01 |
| Single Scope Staging of Lung Cancer With Endosonography (NCT02014324) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2013-05-01 |
| Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (NCT01720836) | Olivera Finn | 2012-11-01 |
| A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib (NCT01712217) | Astex Pharmaceuticals, Inc. | 2012-10-01 |
| A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment (NCT01994057) | Sun Yat-sen University | 2012-09-01 |
| Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation (NCT01637597) | National Taiwan University Hospital | 2012-06-01 |
| Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test) (NCT01620853) | Applied Spectral Imaging Ltd. | 2012-05-01 |
| Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca (NCT02036359) | National Taiwan University Hospital | 2012-05-01 |
| PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy (NCT01666353) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-04-16 |
| Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (NCT01465802) | Pfizer | 2011-12-26 |
| A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer (NCT01454934) | Eisai Inc. | 2011-12-09 |
| Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer (NCT01498562) | Yonsei University | 2011-12-01 |
| Nitroglycerin in Non-small Cell Lung Cancer (NCT01210378) | Maastricht Radiation Oncology | 2011-12-01 |
| Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) (NCT01463423) | Stanford University | 2011-10-21 |
| A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer (NCT01574222) | VA Office of Research and Development | 2011-10-01 |
| Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer (NCT01438307) | University of Alabama at Birmingham | 2011-09-01 |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects (NCT01323062) | UNC Lineberger Comprehensive Cancer Center | 2011-05-01 |
| Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors (NCT01336842) | University of California, Davis | 2011-04-01 |
| A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer (NCT01874678) | TTY Biopharm | 2011-03-01 |
| Pemetrexed in Advanced Non-small Cell Lung Cancer (NCT01193959) | Armando Santoro, MD | 2010-09-01 |
| Study of PX-866 and Docetaxel in Solid Tumors (NCT01204099) | Cascadian Therapeutics Inc. | 2010-09-01 |
| e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer (NCT01359436) | National Taiwan University Hospital | 2010-07-01 |
| A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804 (NCT00971191) | Pfizer | 2010-02-01 |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers (NCT01005797) | Medical University of South Carolina | 2009-11-01 |
| A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) (NCT01028729) | Simcere Pharmaceutical Co., Ltd | 2009-09-01 |
| Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer (NCT00850577) | Bristol-Myers Squibb | 2009-06-01 |
| Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases (NCT00807170) | Sanofi | 2009-05-01 |
| Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer (NCT00821951) | Yale University | 2009-05-01 |
| Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NCT01282437) | Maastricht Radiation Oncology | 2009-01-01 |
| Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (NCT00820755) | Merck KGaA, Darmstadt, Germany | 2009-01-01 |
| Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516 (NCT00818714) | University of Maryland, Baltimore | 2009-01-01 |
| Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) (NCT00793208) | Theresa Whiteside, PhD | 2008-12-01 |
| Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) (NCT00770588) | AstraZeneca | 2008-09-01 |
| Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients (NCT01134250) | Philogen S.p.A. | 2008-08-06 |
| Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer (NCT00683904) | R-Pharm | 2008-06-01 |
| Tarceva Italian Lung Optimization tRial (NCT00637910) | Fatebenefratelli and Ophthalmic Hospital | 2007-11-01 |
| Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT00517790) | AbbVie (prior sponsor, Abbott) | 2007-08-01 |
| Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (NCT00323869) | Stanford University | 2006-06-01 |
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC (NCT00492206) | University of Pittsburgh | 2006-06-01 |
| Phase 2 Trial of Bevacizumab in Combination With Pemetrexed (NCT00227019) | Heather Wakelee | 2006-03-01 |
| An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin (NCT00274443) | Celgene | 2005-03-01 |
| Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (NCT00148798) | Merck KGaA, Darmstadt, Germany | 2004-10-01 |
| Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib (NCT00820417) | Harrison Clinical Research | 2004-06-01 |
| Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA) (NCT00641238) | State University of New York - Upstate Medical University | 2004-03-01 |
| Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC (NCT01947608) | Novartis Pharmaceuticals | |
| Expanded Access to Telisotuzumab Vedotin (NCT04830202) | AbbVie | |
| Expanded Access Use of Cemiplimab in Patients With Solid Tumors (NCT06132191) | Regeneron Pharmaceuticals | |
| Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval (NCT06751524) | Agenus Inc. | |
| Managed Access Programs for LDK378, Ceritinib (NCT05100134) | Novartis Pharmaceuticals | |
| Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment (NCT00683306) | AstraZeneca | |